Novo Nordisk a star amid stodgy pharmaceuticals
May 17, 2010 at 04:59 AM EDT
While the large-cap pharmaceuticals struggle, Novo Nordisk has rallied as its expertise in diabetes pays off. Some say the advance has run too far.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.